Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AIM ImmunoTech Inc.AIM · Entity 8131 | Director · CEO & President | September 17, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AIM ImmunoTech Inc.
Report date September 17, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,822 |
Reported balance
After 2026-09-17 transaction · row 1
1 source rowRow 1 · 2026-09-17 · Purchase · Acquired 24,000 · Balance 126,822 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 18, 2026 12:30 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 24,000 | $0.21 | $4,992.00 |
DisclosureSEC source: 0001493152-26-043246 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,822 Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 16:01 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 11,000 | $0.21 | $2,310.00 |
DisclosureSEC source: 0001493152-26-043073 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,822 Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 13:15 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 22,000 | $0.22 | $4,862.00 |
DisclosureSEC source: 0001493152-26-042848 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,822 Read SEC document |
| September 14, 2026 Filed Sep 15, 2026 20:30 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 5,900 | $0.22 | $1,292.10 |
DisclosureSEC source: 0001493152-26-042754 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,822 Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 21:30 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | ConversionSeries G Convertible Preferred Stock · Derivative | 25 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-010334 · ownership.xml · derivative · entry 2 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: common stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Preferred shares are convertible into common stock at a rate of 1,000 shares of common stock per whole perferred share, effectively $1.00 per share of common stock. F1 · price: The Preferred shares are convertible into common stock at a rate of 1,000 shares of common stock per whole perferred share, effectively $1.00 per share of common stock. F2 · derivative.expiration_date: None Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 21:30 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | ConversionCommon stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-010334 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:56 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | OtherClass G Warrants · Derivative | 50,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009587 · ownership.xml · derivative · entry 3 Equels Thomas K · CIK 0001450324 · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-06 F3 · price: Each warrant is exercisable for one share of common stock at an exercise price of $1.00 per share and was issued as part of a subscription right issued in a rights offering. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:56 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | OtherSeries G Convertible Preferred Stock · Derivative | 25 | $25,000.00 Strike: $1,000.00 | $625,000.00 |
DisclosureSEC source: 0001493152-26-009587 · ownership.xml · derivative · entry 2 Equels Thomas K · CIK 0001450324 · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25 Underlying: Series G Convertible Preferred Stock · 25 shares Expires 2050-03-06 F1 · shares: Each share has a stated value of $1,000 and is convertible into 1,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F2 · derivative.expiration_date: n/a - Preferred shares are perpetual. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 14:53 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 107 | $7.70 | $823.58 |
DisclosureSEC source: 0001641172-25-015207 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,885 Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 15:04 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 103 | $8.70 | $896.10 |
DisclosureSEC source: 0001641172-25-015005 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,675 Read SEC document |
| April 11, 2025 Filed Apr 23, 2025 20:35 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 1,968,504 | $0.03 | $50,000.00 |
DisclosureSEC source: 0001641172-25-005861 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,867,533 F1 · date: Shares purchased pursuant to a purchase agreement executed on April 11, 2025, but first required approval from the NYSE American which was received on April 21, 2025. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 19:42 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 41,000 | $0.06 | $2,583.00 |
DisclosureSEC source: 0001641172-25-002977 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,899,029 Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 14:36 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 50,000 | $0.13 | $6,730.00 |
DisclosureSEC source: 0001493152-25-009338 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,858,029 Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 18:14 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 83,334 | $0.12 | $10,000.08 |
DisclosureSEC source: 0001493152-25-009003 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,764,029 Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 15:00 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 44,000 | $0.12 | $5,060.00 |
DisclosureSEC source: 0001493152-25-009164 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,808,029 Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 18:38 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 22,727 | $0.21 | $4,681.76 |
DisclosureSEC source: 0001493152-24-050757 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,680,695 Read SEC document |
| November 21, 2024 Filed Jan 21, 2025 21:32 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 20,000 | $0.21 | $4,240.00 |
DisclosureSEC source: 0001493152-25-003058 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,657,968 Read SEC document |
| November 20, 2024 Filed Nov 20, 2024 17:46 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 60,110 | $0.18 | $11,000.13 |
DisclosureSEC source: 0001493152-24-046952 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,552,968 Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 17:04 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 85,000 | $0.20 | $16,915.00 |
DisclosureSEC source: 0001493152-24-047094 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,637,968 Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 16:05 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 5,000 | $0.30 | $1,515.00 |
DisclosureSEC source: 0001493152-24-036837 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,493,042 Read SEC document |
| September 13, 2024 Filed Sep 16, 2024 19:45 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 20,000 | $0.31 | $6,160.00 |
DisclosureSEC source: 0001493152-24-036364 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,488,042 Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 21:15 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 312,500 | $0.32 | $100,000.00 |
DisclosureSEC source: 0001493152-24-036076 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,468,042 Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 01:39 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 377,358 | $0.27 | $99,999.87 |
DisclosureSEC source: 0001493152-24-031414 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,155,542 Read SEC document |
| May 06, 2024 Filed May 7, 2024 12:30 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 61,729 | $0.41 | $25,000.25 |
DisclosureSEC source: 0001493152-24-018030 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 778,184 Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 19:01 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 75,758 | $0.33 | $25,000.14 |
DisclosureSEC source: 0001493152-24-010267 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 716,455 Read SEC document |
| November 30, 2023 Filed Mar 27, 2024 17:52 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantOptions · Derivative | 300,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001493152-24-011463 · ownership.xml · derivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-11-30 Read SEC document |
| November 27, 2023 Filed Nov 27, 2023 17:56 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 33,861 | $0.44 | $15,000.42 |
DisclosureSEC source: 0001493152-23-042743 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640,697 Read SEC document |
| September 29, 2023 Filed Sep 29, 2023 19:29 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 22,676 | $0.44 | $10,000.12 |
DisclosureSEC source: 0001493152-23-034802 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 606,836 Read SEC document |
| August 25, 2023 Filed Aug 25, 2023 18:26 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 8,222 | $0.67 | $5,500.52 |
DisclosureSEC source: 0001493152-23-030180 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 584,160 Read SEC document |
| August 24, 2023 Filed Aug 24, 2023 17:52 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 14,993 | $0.67 | $10,000.33 |
DisclosureSEC source: 0001493152-23-030077 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,938 Read SEC document |
| July 17, 2023 Filed Jul 17, 2023 23:20 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 16,950 | $0.59 | $10,000.50 |
DisclosureSEC source: 0001493152-23-024767 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,945 Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 12:30 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 161,291 | $0.31 | $50,000.21 |
DisclosureSEC source: 0001493152-23-000211 · ownership.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,995 Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:50 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantOptions · Derivative | 300,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001493152-22-034332 · ownership.xml · derivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-11-30 F1 · security: Options issued pursuant to employment agreement with Reporting Person. Read SEC document |
| July 18, 2022 Filed Jul 18, 2022 19:01 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 32,895 | $0.76 | $25,000.20 |
DisclosureSEC source: 0001450324-22-000004 · primary_doc.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,704 Read SEC document |
| April 25, 2022 Filed Apr 26, 2022 12:30 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 49,020 | $1.02 | $50,000.40 |
DisclosureSEC source: 0001450324-22-000002 · primary_doc.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,809 Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 15:06 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantOptions · Derivative | 50,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001702626-22-000002 · primary_doc.xml · derivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-03-03 Read SEC document |
| December 13, 2021 Filed Dec 13, 2021 16:43 UTC Amendment | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 21,552 | $1.16 | $25,000.32 |
DisclosureSEC source: 0001450324-21-000013 · primary_doc.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,789 F1 · ownership.direct: Form amended to include reporting person is a director and officer. Read SEC document |
| December 13, 2021 Filed Dec 13, 2021 16:26 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 21,552 | $1.16 | $25,000.32 |
DisclosureSEC source: 0001450324-21-000012 · primary_doc.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,789 Read SEC document |
| December 10, 2021 Filed Dec 10, 2021 15:55 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 11,811 | $1.27 | $14,999.97 |
DisclosureSEC source: 0001450324-21-000011 · primary_doc.xml · nonDerivative · entry 1 Equels Thomas K · CIK 0001450324 · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,237 Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 18:51 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 11,627 | $1.29 | $14,998.83 |
DisclosureSEC source: 0001702626-21-000002 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,426 Read SEC document |
| November 23, 2021 Filed Nov 23, 2021 16:08 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 11,194 | $1.34 | $14,999.96 |
DisclosureSEC source: 0001450324-21-000009 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,799 Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 16:28 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 10,204 | $1.47 | $14,999.88 |
DisclosureSEC source: 0001450324-21-000008 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,605 Read SEC document |
| November 17, 2021 Filed Nov 17, 2021 22:27 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 9,146 | $1.64 | $14,999.44 |
DisclosureSEC source: 0001450324-21-000007 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,401 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 21:57 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantOptions · Derivative | 300,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001450324-21-000004 · primary_doc.xml · derivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-11-11 Read SEC document |
| July 16, 2021 Filed Jul 16, 2021 16:07 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 15,625 | $1.92 | $30,000.00 |
DisclosureSEC source: 0001450324-21-000002 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,255 Read SEC document |
| February 24, 2021 Filed Feb 24, 2021 17:03 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 11,062 | $2.26 | $25,000.12 |
DisclosureSEC source: 0001450324-21-000001 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,630 Read SEC document |
| December 17, 2020 Filed Dec 17, 2020 17:22 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 14,535 | $1.72 | $25,000.20 |
DisclosureSEC source: 0001450324-20-000008 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,568 Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:38 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantOptions · Derivative | 300,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001450324-20-000007 · primary_doc.xml · derivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-11-11 Read SEC document |
| September 03, 2020 Filed Sep 3, 2020 14:53 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 12,316 | $2.03 | $25,001.48 |
DisclosureSEC source: 0001450324-20-000006 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,033 Read SEC document |
| August 21, 2020 Filed Aug 21, 2020 12:08 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | PurchaseCommon Stock | 10,730 | $2.33 | $25,000.90 |
DisclosureSEC source: 0001450324-20-000005 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,717 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.